TechFW@UTA to propel University research, innovation toward commercialization

October 21, 2013

ARLINGTON, TX - The University of Texas at Arlington and TechFW, a Fort Worth-based technology startup initiative, have agreed to a multi-year partnership to commercialize University research and move innovation to the marketplace.

TechFW@UTA will offer training and educational programs to UT Arlington faculty, staff and students. UT Arlington faculty members and research teams will gain access to the North Texas entrepreneurial community through the TechFW network.

The partnership comes as UT Arlington's research profile continues to accelerate. The Univeristy tallied $77.7 million in total research expenditures in the 2012-2013 fiscal year that ended Aug. 31.

"Research and technologies developed by a major research institution like UT Arlington have the power to generate business and strengthen the region's economy," said Carolyn Cason, UT Arlington vice president for research. "This collaboration with TechFW will be an important catalyst for helping the private sector capitalize on UT Arlington innovation to benefit a broad range of businesses and industries." Darlene Boudreaux, executive director of TechFW, said the new relationship creates significant opportunities for her organization's other clients, as well.

"There will be plenty of economic opportunities for our existing clients to access the tremendous resources available at UT Arlington," Boudreaux said. "We look forward to teaming with UT Arlington entities like the UT Arlington Research Institute and the Shimadzu Institute for Research Technology, and with professors who have secured numerous national grants."

TechFW was formed in 1998 as a nonprofit organization to diversify the Fort Worth economy through an emphasis on new technologies. Originally funded by private foundations, TechFW is now supported by the City of Fort Worth, the University of North Texas Health Science Center in Fort Worth, The University of Texas at Arlington, Texas Christian University and corporate donors from across North Texas.

The agency's mission is to encourage the development of the technology business community by helping regional entrepreneurs commercialize innovative technologies.

Among the TechFW success stories is ZS Pharma, a pharmaceutical company that moved to Texas in 2010 and partnered with TechFW's to help move a new drug to market. TechFW matched the company with local service providers, providing lab space, identifying management team members and securing initial funding for the company. Since then, ZS Pharma has raised more than $70 million in funding and the drug is in phase 3 of clinical trials, Boudreaux said. UT Arlington faculty and researchers will have access to exitsting TechFW offices at Fort Worth's James E. Guinn School facility, 1120 South Freeway, and at the University of North Texas Health Science Center's Acceleration Lab, 3400 Camp Bowie Blvd.

But TechFW will also maintain offices at the UT Arlington Office of Research Administration, 202 E. Border St., and eventually in the College of Business. UT Arlington faculty and researchers will have access to TechFW's core programs, including an Incubation Workshop, the Acceleration Program, Tech Nest, the Cowtown Angels Network and TechFW's biweekly, online radio show, Tech Talk - Texas Style.

The agency also plans to establish a new program called Breakthough at UT Arlignton that will identify identify commercial value of research projects and will communicate with and engage stakeholders early in the research process.

"Breakthrough will afford up to 20 UT Arlington researchers a year the opportunity to better focus their discovery or invention for the investor community," Boudreaux said. "Researchers and professors will gain insight into how business people think and how to move their concepts closer toward market applications."
About The University of Texas at Arlington

The University of Texas at Arlington, a comprehensive research institution of more than 33,300 students and more than 2,200 faculty members in the heart of North Texas. It is the second largest institution in The University of Texas System. Visit to learn more.


TechFW encourages the development of the technology business community by helping regional entrepreneurs commercialize innovative technology. The nonprofit organization identifies entrepreneurs and startup companies with technologies that have a high potential for success in the marketplace, then matches resources of the community with the passion of entrepreneurs, and then mentor, coach, and relentlessly push the entrepreneurs toward success.

University of Texas at Arlington

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to